Connect Biopharma Holdings Limited
CNTB · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $2 | $24 | $0 |
| % Growth | -97.5% | -92.1% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $2 | $24 | -$0 |
| % Margin | 100% | 90.4% | 98% | – |
| R&D Expenses | $9 | $16 | $13 | $25 |
| G&A Expenses | $5 | $12 | $7 | $0 |
| SG&A Expenses | $5 | $12 | $7 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $6 |
| Other Operating Expenses | $0 | -$1 | -$4 | -$4 |
| Operating Expenses | $13 | $27 | $17 | $28 |
| Operating Income | -$13 | -$25 | $7 | -$27 |
| % Margin | -27,966.7% | -1,302.6% | 30.3% | – |
| Other Income/Exp. Net | $1 | $2 | $0 | -$2 |
| Pre-Tax Income | -$13 | -$23 | $8 | -$29 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$13 | -$23 | $8 | -$29 |
| % Margin | -26,872.9% | -1,214.2% | 31.7% | – |
| EPS | -0.23 | -0.42 | 0.14 | -0.52 |
| % Growth | 45.2% | -400% | 126.9% | – |
| EPS Diluted | -0.23 | -0.42 | 0.14 | -0.52 |
| Weighted Avg Shares Out | 55 | 55 | 55 | 55 |
| Weighted Avg Shares Out Dil | 55 | 55 | 56 | 55 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $4 | $1 | -$2 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$13 | -$23 | $8 | -$28 |
| % Margin | -27,610.4% | -1,196.1% | 34% | – |